Introduction
Microglial cells, the resident immune cells of the central nervous system (CNS), share a number of phenotypic characteristics and lineage properties with other bone marrowderived myeloid cell populations, and are regarded as members of the monocyte/macrophage lineage. Microglia originate from primitive myeloid progenitors that arise early in embryonic development, and constitute an ontogenetically distinct population in the mononuclear phagocyte system. They are highly plastic and, by virtue of their location and current role in the nervous tissue, are able to undergo a variety of morphological and functional changes in response to various stimuli. Resting microglia display a ramified morphology characterized by numerous, fine-branched processes with relatively small somata and subdued macrophage-like functional properties. In response to neural injury, infection and inflammatory or other signals, microglia become activated and undergo a series of morphological, molecular and functional changes in proportion to the severity of the damage to the neuronal tissue. They become progressively less ramified and quickly develop an enlarged cell body with several short, thickened processes (activated microglia) that may eventually completely retract (phagocytic microglia). This coincides with their antigen presentation ability and cytotoxic and inflammation-mediating signalization.
As regards origin, there are two populations of microglial cells in the CNS at any given time. The resident microglia comprise a distinct pool of cells that respond to stimuli and proliferate accordingly, and regulate their population dynamics in a manner dependent on the severity of the tissue damage. They exhibit an extremely slow turnover with the bone marrow, lack the major histocompatibility complex (MHC) class I/MHC class II proteins, interferon-γ, cytokines, CD45 antigens and many other surface receptors required to serve in the antigen-presenting, phagocytic and cytotoxic roles characteristic of the normal macrophage functions. Another population of cells, however, among which the perivascular microglial cells are prominent in number, is located in the close vicinity of blood vessels, and can be replaced regularly by bone marrow-derived precursor cells that express MHC class II antigens, indicating their monocyte/macrophage origin. In cases of extreme damage to the CNS, as in infection or stroke, the blood-brain barrier may weaken considerably, and hematogenous, bone marrow-derived cells, such as myeloid progenitor cells and macrophages, may enter the brain. Once the damage has abated, the peripheral and central systems are disconnected for the recovery and regrowth period.
Similarly to the extensive studies on the origin and the morphological and can also exert their effects on some of the CaM-regulated targets directly.
Specific aims
Under physiological conditions, the vast majority of the resident microglia in the CNS are 
Materials and methods
All animal experiments were carried out in strict compliance with the European Council The number of microglia increased from 0.5% to 33.7% during culturing.
2) In mixed primary cultures, TI values revealed the evolving microglial morphology and functions during culturing as microglia with TI < 3 were more active in phagocytosing than the ramified forms characterized with TI > 3.
3) The macrophage/microglia markers labelled different microglial phenotypes in culture: HLA DP, DQ, DR-positive microglia were exclusively ameboid, while
CD11b/c-labeled microglia were typically less ramified than the Iba1-labeled cells. CD11b/c-positive microglia in cultures older than DIV10 were no longer able to express any of these HLA antigens. 
